Adaptimmune Therapeutics plc (ADAPY) Stock Price & Analysis
Adaptimmune Therapeutics plc (ADAPY) — price $0.037 (-2.63%), as of the Oct 2, 2026 trading session; market cap $9.81M.
Educational signal · not a buy or sell recommendation · How to read this
Adaptimmune Therapeutics plc · ADAPY
Adaptimmune Therapeutics plc is a commercial-stage biopharmaceutical company focused on developing novel T-cell immunotherapies for cancer patients in the US and UK. Leveraging its genetically modified autologous T-cell platform, the company advances therapies like TECELRA for synovial sarcoma, alongside a pipeline targeting various cancers through strategic collaborations, positioning it in the specialized cell therapy market.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore is not published for this security.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.037 | |
| Change on the day | -2.63% | |
| 52-week range | $0.001 – $0.275 | |
| Market capitalisation | $9.81M | |
| Shares traded on the day | 16.0K |
Price & events
Other perspectives
Council score for Adaptimmune Therapeutics (ADAPY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 4, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the ADAPY film — every key number, told as a short cinematic story
~2 min · open the film
What is Adaptimmune Therapeutics (ADAPY), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Adaptimmune Therapeutics plc (ADAPY) is the company analyzed here. It employs 272 people and is led by Christopher James Hill. In Q2 FY2025 it reported revenue of $14M and net income of -$30M. The market values it at $9.81M.
What do the latest results show for Adaptimmune Therapeutics (ADAPY)?
Short answer · as of
The most recent reported quarter, Q2 FY2025, carried revenue of $14M. Against analyst estimates the company has EPS beat 4 of 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2025 | $14M | -$30M | -$0.11 (diluted) |
| Q1 FY2025 | $7M | -$48M | -$0.19 (diluted) |
| Q4 FY2024 | $3M | -$74M | -$0.29 (diluted) |
| Q3 FY2024 | $41M | -$18M | -$0.07 (diluted) |
What are the financial strengths and risks for Adaptimmune Therapeutics (ADAPY)?
Short answer
The distress and quality screens read Altman Z -15.85 · Piotroski F 0. Trailing ratios: ROE 472.8% · current ratio 1.52.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -15.85 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
What should you watch next at Adaptimmune Therapeutics (ADAPY)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $20.70M · EPS -0.50 · 1 analysts.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- The newest quarter held here (Q2 FY2025) was filed Aug 13, 2025 — 9 months ago.
Checked against the records this page reads, on the dates shown above.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $20.70M
- EPS estimate
- $-0.50
Measured against a quoted price of $0.037 (as of Oct 2, 2026).
Insider activity
Form 4 records via FMP · Most recent available transactions
- Transactions
- 12
- Identified insiders
- 6
- Purchases
- 0
- Sales
- 7
- Other transactions
- 5
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
What Investors Ask About Adaptimmune Therapeutics (ADAPY)
These answers are editorial: 1 of these 8 answers is drawn from the ADAPY research dossier (written Jun 13, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is ADAPY a good stock to buy?
Stock Expert AI does not rate ADAPY buy, sell or hold. Adaptimmune Therapeutics plc has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the ADAPY stock price today?
The last price recorded on this page for Adaptimmune Therapeutics plc (ADAPY) is $0.037, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the implications of Adaptimmune Therapeutics plc trading on the OTC market?
Trading on the "OTC Other" tier of the OTC market carries several implications for Adaptimmune Therapeutics plc and its investors.
What are the key factors to evaluate for ADAPY?
Evaluate ADAPY on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does ADAPY data refresh on this page?
ADAPY's price is the last quote we recorded, from the Oct 2, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven ADAPY's recent stock price performance?
Adaptimmune Therapeutics plc (ADAPY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Commercial-stage product (TECELRA) addressing an unmet medical need in synovial sarcoma. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ADAPY overvalued or undervalued right now?
Adaptimmune Therapeutics plc (ADAPY) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research ADAPY before investing?
Before investing in Adaptimmune Therapeutics plc (ADAPY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 13, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (18 figures)
The 18 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 9 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $0.037 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T12:34:27.030Z. | |
px.change | Change on the day | -2.63% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $9.81M | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:00.000Z. Captured from FMP at 2026-10-04T12:34:25.838Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | −$0.001 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 16.0K | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2025 | $14M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q2 FY2025 | -$30M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2025 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
own.insiders | Insider transactions via FMP | 12 transactions · 0 purchases, 7 sales, 5 other transactions · 6 identified insiders · most recent available transactions | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. |
UNRECORDED — 9 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $0.001 – $0.275 | UNRECORDED | Stored company-profile observation — Captured 2026-10-03 | |
id.employees | Employees | 272 | UNRECORDED | Stored company-profile observation — Captured 2026-10-03 | |
id.ceo | Chief executive | Christopher James Hill | UNRECORDED | Stored company-profile observation — Captured 2026-10-03 | |
earn.history | Reported versus estimated, recent quarters | EPS beat 4 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-09-10 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z -15.85 · Piotroski F 0 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-03 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 472.8% · current ratio 1.52 | — | UNRECORDED | Stored key metrics — Date unknown |
earn.estimates | Analyst estimates, next fiscal year | FY2026 revenue $20.70M · EPS -0.50 · 1 analysts | UNRECORDED | Stored analyst estimates — Captured 2026-06-16 · Expired observation | |
earn.est_revenue | Revenue estimate, FY2026 | $20.70M | UNRECORDED | Stored analyst estimates — Captured 2026-06-16 · Expired observation | |
earn.est_eps | EPS estimate, FY2026 | $-0.50 | UNRECORDED | Stored analyst estimates — Captured 2026-06-16 · Expired observation |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.